The Launch of the PaCNOD Pilot Study: A New Hope for Early Detection

QIMR Berghofer Medical Research Institute, one of Australia's leading cancer research hubs, has recently launched the PaCNOD Pilot Study, marking a significant step forward in pancreatic cancer early detection efforts. This innovative initiative targets individuals newly diagnosed with diabetes, exploring whether routine screening could uncover hidden pancreatic tumors before they advance to deadly stages. Pancreatic cancer remains one of the most lethal diseases, with most cases diagnosed too late for effective treatment. By leveraging the known association between new-onset diabetes and pancreatic cancer, researchers aim to refine screening protocols that could save lives through timely intervention.

The study, formally known as the Pancreatic Cancer New Onset Diabetes Study, is led by Professor Rachel Neale from QIMR Berghofer's Cancer Aetiology and Prevention Laboratory. Collaborating with experts from the University of Queensland, University of Melbourne, and several major hospitals, the project underscores the vital role of interdisciplinary higher education partnerships in advancing medical breakthroughs. As recruitment opens Australia-wide, this pilot represents a feasible pathway toward larger clinical trials, potentially transforming how we approach high-risk populations.

Unraveling the Link Between New-Onset Diabetes and Pancreatic Cancer

New-onset diabetes, particularly in adults over 50, can sometimes signal an underlying pancreatic issue. In rare instances—estimated at about 1 in 175 cases for those aged 50 and older—this form of diabetes, often termed type 3c diabetes mellitus (pancreatogenic diabetes), arises because a pancreatic tumor disrupts insulin production. Globally and in Australia, studies show that individuals with recent diabetes diagnoses face a 2- to 8-fold increased risk of developing pancreatic cancer compared to the general population.

Pancreatic ductal adenocarcinoma (PDAC), the most common type, frequently presents with subtle symptoms like unexplained weight loss, jaundice, or sudden diabetes. Unlike type 2 diabetes, which affects over 1.3 million Australians predominantly through lifestyle and genetic factors, type 3c stems directly from pancreatic damage. Researchers hypothesize that imaging high-risk diabetics could identify precancerous lesions or early tumors, shifting diagnosis from stage IV (90% of cases) to operable stages where survival odds improve dramatically.

Study Design and Procedures: A Step-by-Step Approach

The PaCNOD Pilot Study employs a multi-phase design to ensure practicality and ethics. Participants begin with a comprehensive 30-minute online survey assessing health history, symptoms, and risk factors. Following this, they consent to data linkage from Medicare and the Pharmaceutical Benefits Scheme (PBS), allowing researchers to access medical records without invasive measures for all.

• Survey Completion: Demographic and clinical details collected remotely.
• Data Consent: Secure access to GP notes and national health databases.
• Selective Imaging: Eligible subsets undergo a kidney function blood test followed by a low-radiation contrast-enhanced computed tomography (CT) scan of the abdomen, performed locally for convenience.

As a pilot, the focus is on logistics: recruitment rates, participant retention, scan uptake, and false-positive minimization. Compensation includes a $50 e-gift card, incentivizing involvement while covering time costs. This structured process mirrors rigorous clinical trial standards upheld in Australian higher education-linked research.

Who Can Participate? Eligibility and Recruitment Pathways

To join, individuals must be 55 years or older, hold a Medicare card, have a recent diabetes diagnosis (typically within months), and no prior pancreatic history or surgery. Access to an internet-enabled device is required for the survey. GPs play a crucial role, referring suitable patients via a dedicated portal to streamline ethical recruitment.

Recruitment is nationwide, with scans available near homes or workplaces to reduce barriers. Contact via email (PaCNOD@qimrb.edu.au), phone (1300 735 920), or the QIMR website ensures broad reach. Early participants, like 58-year-old Paul Williams—the first to enroll—highlight personal stakes, driven by family history and a quest for proactive care.

The Expert Team Driving Innovation at QIMR Berghofer

Professor Rachel Neale, a behavioral epidemiologist with decades in cancer prevention, heads the effort. Her team at QIMR Berghofer collaborates with University of Queensland's Susan Jordan and Manil Chouhan, University of Melbourne's Jon Emery, and clinicians from Royal Brisbane Hospital and beyond. International input from MD Anderson Cancer Center and the US Pancreatic Cancer Action Network adds global rigor.

This network exemplifies how Australian universities and institutes foster translational research. For aspiring researchers, opportunities abound in clinical trials and epidemiology. Career advice for research assistants in such projects emphasizes data ethics and patient-centered design.

Photo by Cht Gsml on Unsplash

Pancreatic Cancer's Grim Reality in Australia

Australia faces a rising pancreatic cancer tide: 4,825 estimated new cases in 2025, claiming 4,039 lives—the third-leading cancer killer. Incidence has doubled in two decades, with age-standardized rates climbing. Five-year survival hovers at 13.5% (2017-2021), up slightly from 6.5% earlier but dismal compared to breast cancer's 90%.

Over 90% diagnoses occur post-metastasis, limiting curative options. Men face higher rates (ASR 6.5/100,000 vs. 5.2 women), peaking post-70. With 1.3 million diabetics—59% over 65—screening subsets could yield substantial gains. AIHW data underscores urgency: without early tools, mortality persists high.

Overcoming Barriers to Early Detection

Pancreatic cancer evades early spotting due to vague symptoms mimicking indigestion or diabetes. No routine screening exists like mammograms; CA19-9 blood tests lack specificity. CT/MRI sensitivity improves with risk stratification, but radiation/cost concerns demand pilots like PaCNOD.

• False Positives: Avoided via targeted eligibility.
• Equity: Nationwide access counters rural-urban disparities.
• Ethics: Informed consent prioritizes psychological impacts.

QIMR's Pathways Study complements by mapping diagnostic delays, informing holistic strategies.

QIMR Berghofer's Broader Pancreatic Cancer Portfolio

Beyond PaCNOD, QIMR advances genomics (Dr. Nic Waddell's team sequencing tumors for immunotherapy targets), epigenetics (Assoc. Prof. Jason Lee probing gene regulation), and prevention trials. The PRoCESS service tests telehealth counseling for at-risk families, bridging research to care.

Affiliated with University of Queensland, these efforts attract top talent. Explore research positions in oncology at Australian institutes fuel such innovations.

Patient Perspectives and Expert Insights

First enrollee Paul Williams shares: "If it's cancer and not caught early, life expectancy goes downhill quickly." Prof. Neale emphasizes: "Pancreatic cancer is notoriously difficult to detect early... screening higher-risk patients could transform outcomes."

These voices humanize the science, highlighting hope amid statistics. GPs note the 1-in-175 odds justify piloting without over-screening.

Future Implications and Research Horizons

Success could spawn national screening guidelines, akin to fecal occult blood tests for colorectal cancer. Broader impacts: reduced healthcare costs, better survival (potentially tripling 5-year rates), and diabetes management insights. Ongoing trials like vitamin D supplementation test prevention.

For higher education, this spotlights clinical research careers. Postdoc opportunities in cancer epidemiology abound.

Photo by Logan Voss on Unsplash

Getting Involved: Careers and Support in Pancreatic Research

Australia's med research ecosystem thrives on talent. QIMR Berghofer and partners seek postdocs, research assistants, and lecturers. Australian academic jobs in health sciences grow, with demand for epidemiologists.

Patients/families: Join via QIMR or support Pankind. Academics: Collaborate on trials advancing global standards. Rate your professors and share experiences shaping future researchers. Explore higher-ed-jobs, university-jobs, and higher-ed-career-advice for pathways into oncology research.